XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।

XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।
A
A

Amgen

समाचार

Reuters - 1 दिन पहले

US drugmakers muted after Trump's election victory

BUZZ-US drugmakers muted after Trump's election victory Updates ** U.S. drugmakers' shares trading up between 0.5% and 1% after Donald Trump elected as U.S. president ** Gilead GILD.O gains 1.4%, while Abbvie ABBV.N , Amgen AMGN.O Merck MRK.N , Bristol Myers BMY.N and J&J JNJ.N rise marginally ** Leerink analysts said they view Trump's win as mixed for large-cap biopharma since it creates potential uncertainty regarding U.S.
A
G
P
Reuters - 2 दिन पहले

US drugmakers rise as Trump wins second US presidential term

BUZZ-US drugmakers rise as Trump wins second US presidential term ** Shares of some U.S. drugmakers rise between 1% and 3% premarket as Donald Trump wins second term at the White House ** Eli Lilly LLY.N shares gain 2.8%, Abbvie ABBV.N up about 2%, Amgen AMGN.O shares rise 1.5%, and Merck MRK.N up 1.3% ** Gilead GILD.O gains 1.2%, while Pfizer PFE.N and Bristol Myers BMY.N inch up about 1% in premarket trading ** BMO Capital had said ahead of elections that a Trump victory would be "net positive
A
G
P
Reuters - 3 दिन पहले

MaxCyte Inc <MXCT.OQ> expected to post a loss of 12 cents a share - Earnings Preview

MaxCyte Inc expected to post a loss of 12 cents a share - Earnings Preview MaxCyte Inc MXCT.OQ MXCT.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2024 The Rockville Maryland-based company is expected to report a 7.9% decrease in revenue to $7.374 million from $8 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
A
Reuters - 6 दिन पहले

MacroGenics Inc <MGNX.OQ> expected to post earnings of 21 cents a share - Earnings Preview

MacroGenics Inc expected to post earnings of 21 cents a share - Earnings Preview MacroGenics Inc MGNX.OQ MGNX.O is expected to show a rise in quarterly revenue when it reports results on November 5 for the period ending January 1 0001 The Rockville Maryland-based company is expected to report a 632.1% increase in revenue to $76.115 million from $10.4 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
A
Reuters - 1 सप्ताह पहले

U.S. Altair Engineering, Brinker International, Meta

U.S. RESEARCH ROUNDUP-Altair Engineering, Brinker International, Meta Oct 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Altair Engineering, Brinker International and Meta, on Thursday. HIGHLIGHTS * Altair Engineering Inc ALTR.O : Needham cuts to hold from buy * Blackbaud Inc BLKB.O : Baird cuts to neutral from outperform * Brinker International Inc EAT.N : JP Morgan cuts to neutral from overweight * Comstock Res
A
A
B
B
C
C
E
G
I
M
S
V
V
A
A
C
K
E
C
Reuters - 1 सप्ताह पहले

Amgen Inc reports results for the quarter ended in September 30 - Earnings Summary

Amgen Inc reports results for the quarter ended in September 30 - Earnings Summary Amgen Inc AMGN.OQ reported quarterly adjusted earnings of $5.58​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $4.96. The mean expectation of twenty two analysts for the quarter was for earnings of $5.11 per share.
A
Reuters - 1 सप्ताह पहले

Amgen posts higher profit, obesity data on track for late this year

UPDATE 2-Amgen posts higher profit, obesity data on track for late this year Updates share price, adds analyst comment paragraphs 17-18 By Deena Beasley Oct 30 (Reuters) - Amgen AMGN.O reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and osteoporosis, and said mid-stage trial results for a potentially lucrative obesity medicine will be unveiled late this year.
A
Reuters - 1 सप्ताह पहले

Amgen Reports Third Quarter 2024 Financial Results

BRIEF-Amgen Reports Third Quarter 2024 Financial Results Oct 30 (Reuters) - Amgen Inc AMGN.O : AMGEN Q3 ADJUSTED EPS $5.58 VERSUS IBES ESTIMATE $5.11 AMGEN OUTLOOK FY ADJUSTED EPS $19.20 TO $20.00 VERSUS IBES ESTIMATE $19.49 AMGEN OUTLOOK FY TOTAL REVENUE $33.0 BILLION TO $33.8 BILLION VERSUS IBES ESTIMATE $33.21 BILLION AMGEN OUTLOOK FY SHARE REPU
A
Reuters - 1 सप्ताह पहले

Amgen posts higher 3rd-quarter profit, sales rise 24%

Amgen posts higher 3rd-quarter profit, sales rise 24% By Deena Beasley Oct 30 (Reuters) - Amgen AMGN.O reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug Repatha and Prolia for osteoporosis, and said results of a mid-stage trial of a potentially lucrative obesity medicine will be unveiled late this year.
A
Reuters - 1 सप्ताह पहले

U.S. STOCKS Zimmer Biomet, Shake Shack, Microsoft

BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes advanced on Wednesday, with the tech-heavy Nasdaq rising to a record high, as investors assessed corporate earnings as well as crucial data showing the economy maintained a steady pace of growth in the third quarter.
A
A
B
C
C
D
E
G
M
M
N
Q
Q
V
A
K
S
U
U
G
W
Z
D
F
O
Reuters - 1 सप्ताह पहले

PREVIEW: Amgen edges lower with results on tap

BUZZ-PREVIEW: Amgen edges lower with results on tap ** Amgen AMGN.O shares down 0.1% to $315.56 ahead of Q3 results due after the closing bell on Weds ** The biotech company is expected to report adj EPS of $5.11 on revenue of $8.52 bln, per LSEG data, vs yr-ago results of $4.96 in EPS and $6.9 bln in revenue ** AMGN has met or beaten EPS view in 6
A
U
Reuters - 1 सप्ताह पहले

Alphabet beats and Treasuries rally

MORNING BID AMERICAS-Alphabet beats and Treasuries rally A look at the day ahead in U.S. and global markets from Mike Dolan Markets struggling which way to look will be dizzy again in an event-strewn Wednesday but the spotlight first thing drops on Alphabet's GOOGL.O impressive earnings beat and a relief-rally in election-bruised U.S. Treasuries. A critical fortnight for investors includes next week's U.S.
A
B
B
C
E
G
G
I
M
M
P
U
U
V
V
A
A
K
J
U
U
U
U
G
I
P
Reuters - 2 सप्ताह पहले

Roche comes out against allowing takeover of drug manufacturer Catalent

UPDATE 5-Roche comes out against allowing takeover of drug manufacturer Catalent Adds comment from Novo Holdings in paragraph 13 Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy groups also voice concerns over the deal Novo Nordisk and Catalent defend the acquisition, citing ample competition By Ludwig Burger FRANKFURT, Oct 23 (Reuters) - The CEO of p
A
A
P
R
Reuters - 2 सप्ताह पहले

Regeneron loses bid to block Amgen's Eylea biosimilar launch in US

UPDATE 1-Regeneron loses bid to block Amgen's Eylea biosimilar launch in US Adds comments from Regeneron and Amgen in paragraphs 3-4, additional context in paragraphs 5-8 By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said.
A
R
Reuters - 2 सप्ताह पहले

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case

Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case By Blake Brittain Oct 22 (Reuters) - Amgen AMGN.O will launch its biosimilar version of Regeneron's REGN.O blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to temporarily block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
A
R
Reuters - 2 सप्ताह पहले

Biotech M&A to show less 'fire power' in 2024 due to low-valued deals

LIVE MARKETS-Biotech M&A to show less 'fire power' in 2024 due to low-valued deals Main U.S. indexes red; Dow off most, down ~0.8% Real Estate weakest S&P sector; Tech sole gainer Dollar up; crude gains ~2%; gold ~flat; bitcoin down ~2.5% U.S. 10-Year Treasury yield jumps to ~4.18% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
A
B
G
P
V
U
U
Reuters - 3 सप्ताह पहले

U.S. Centerspace, Gilead, Gitlab

U.S. RESEARCH ROUNDUP-Centerspace, Gilead, Gitlab Oct 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Centerspace, Gilead and Gitlab, on Monday. HIGHLIGHTS * Centerspace CSR.N : Raymond James cuts to market perform from outperform * Euronet Worldwide Inc EEFT.O : Citigroup cuts to neutral from buy * Gilead GILD.O : Leerink Partners raises to outperform from market perform * Gitlab Inc GTLB.O : Needham raises to bu
A
A
B
M
P
F
U
E
S
B
L
L
M
Reuters - 3 सप्ताह पहले

Consumer groups ask FTC to block Novo Holdings-Catalent deal

UPDATE 7-Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing Adds Novo Holdings comment in paragraph 7 By Jody Godoy and Maggie Fick NEW YORK, Oct 18 (Reuters) - U.S.
A
A
N
N
P
R
Reuters - 3 सप्ताह पहले

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing By Jody Godoy, Maggie Fick NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S.
A
A
N
N
P
R
Reuters - 3 सप्ताह पहले

U.S. Constellation Energy, Morgan Stanley, Uber

U.S. RESEARCH ROUNDUP-Constellation Energy, Morgan Stanley, Uber Oct 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Morgan Stanley, and Uber, on Thursday. HIGHLIGHTS * Constellation Energy Corp CEG.O : J.P. Morgan initiates coverage with overweight rating * Illumina Inc ILMN.O : HSBC raises to buy from hold * Morgan Stanley MS.N : RBC raises target price to $122 from $108 * Uber UBER.N : Dai
A
A
A
B
B
C
C
C
G
I
S
V
U
U
G
U
W
A
A
C
C
D
D
F
F
P

स्थितियाँ

लोकप्रिय परिसंपत्तियाँ

अस्वीकरण: XM Group के सत्व केवल निष्पादन वाली सेवा और हमारी ऑनलाइन व्यापार सुविधा में पहुँच प्रदान करते हैं, ताकि व्यक्ति वेबसाइट पर या उसके जरिए उपलब्ध सामग्री को देख सके और/या उसका उपयोग कर सके। इसका प्रयोजन इसे बदलना या विस्तार देना नहीं है, न ही वह इसे बदलता या विस्तार देता है। इस तरह की पहुँच हमेशा ही निम्नलिखित के अधीन रहेगी: (1) नियम और शर्तें; (2) जोखिम चेतावनियाँ; और (3) पूर्ण अस्वीकरण। इसलिए ऐसी जानकारी सामान्य सूचना से अधिक कुछ भी नहीं है। विशेष रूप से, कृपया इससे अवगत रहें कि हमारी ऑनलाइन व्यापार सुविधा की सामग्रियाँ न तो किसी चीज का अनुरोध करती हैं, न ही वित्तीय बाजारों में प्रवेश करने की पेशकश ही करती हैं। किसी भी वित्तीय बाजार में व्यापार करने के साथ आपकी पूँजी को उल्लेखनीय जोखिम है।

हमारी ऑनलाइन व्यापार सुविधा में प्रकाशित सभी सामग्रियाँ शैक्षणिक/सूचनात्मक प्रयोजनों मात्र के लिए हैं, और इनमें वित्तीय, निवेश टैक्स या व्यापार सलाह और सुझाव नहीं हैं - न ही ऐसा समझना चाहिए कि इनमें ये सब हैं; न ही इनमें हमारी व्यापार कीमतों का अभिलेख है; न ही इनमें किसी वित्तीय उपकरण में लेन-देन करने का निमंत्रण या अनुरोध है; न ही ये आपको अवांछित वित्तयी प्रोमोशन पेश करती हैं।

इस वेबसाइट में मौजूद कोई भी तृतीय पक्षीय सामग्री, तथा XM द्वारा तैयार की गई सामग्रियाँ, जैसे: अभिप्राय, समाचार, अनुसंधान, विश्लेषण, कीमतें और अन्य सूचनाएँ या तृतीय पक्षों की साइटों के लिंक, "जैसा-है-वैसा" के आधार पर बाजार के बारे में सामान्य टिप्पणी के रूप में उपलब्ध कराई गई हैं, और वे निवेश हेतु सलाह नहीं हैं। जिस हद तक कीसी सामग्री को निवेश अनुसंधान मान लिया जाता है, उस हद तक आपको ध्यान में रखना होगा और इसे स्वीकार करना होगा कि वह सामग्री इस उद्देश्य से और निवेश अनुसंधान की स्वतंत्रता को बढ़ावा देने के लिए कानूनी आवश्यकताओं के मुताबिक, तैयार नहीं की गई है, और इसलिए उसे प्रासंगिक कानूनों और विनियमों के तहत विपणन संप्रेषण माना जाएगा। कृपया सुनिश्चित करें कि आपने गैर-आश्रित निवेश के बारे में हमारी सूचना को पढ़ और समझ लिया है। पीछे दी गई जानकारी के बारे में अनुसंधान और जोखिम चेतावनी यहाँ उपलब्ध है।

जोखिम की चेतावनी: आपकी पूँजी जोखिम में है। लीवरेज वाले उत्पाद सबके उपयुक्त नहीं होते हैं। कृपया हमारे जोखिम खुलासे पर विचार करें।